Q4 2023 · 13F-HR
Atlas Venture Life Science Advisors, LLCholdings as filed
Filed 2024-02-09 · accession 0001104659-24-012910
$839.8M
Reported value
16
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $149.2M | 17.8% | 5,858,262 | Common | SOLE |
| 254604101 | IRON | Disc Medicine, Inc. | $147.6M | 17.6% | 2,555,172 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics, Inc. | $131.5M | 15.7% | 9,885,449 | Common | SOLE |
| 88427A107 | — | Third Harmonic Bio, Inc. | $119.7M | 14.2% | 10,907,859 | Common | SOLE |
| 23954D109 | DAWNGBX | Day One Biopharmaceuticals, Inc. | $111.1M | 13.2% | 7,608,394 | Common | SOLE |
| 500946108 | KRRO | Korro Bio, Inc. | $53.6M | 6.39% | 1,119,292 | Common | SOLE |
| 008064107 | — | Aerovate Therapeutics, Inc. | $46.1M | 5.50% | 2,039,249 | Common | SOLE |
| 92673K108 | VIGL | Vigil Neuroscience, Inc. | $19.7M | 2.35% | 5,836,874 | Common | SOLE |
| 76029N106 | REPL | Replimune Group, Inc. | $17.7M | 2.11% | 2,098,300 | Common | SOLE |
| 37148K100 | GBIOGBX | Generation Bio, Co. | $13.7M | 1.63% | 8,279,484 | Common | SOLE |
| 45175G108 | — | Ikena Oncology, Inc. | $9.9M | 1.18% | 5,018,178 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics, Inc. | $8.4M | 1.00% | 359,251 | Common | SOLE |
| 05455M100 | — | AvroBio, Inc. | $6.2M | 0.74% | 4,541,381 | Common | SOLE |
| 252828108 | DNTH | Dianthus Therapeutics, Inc. | $2.5M | 0.29% | 236,979 | Common | SOLE |
| 98422T100 | — | Xilio Therapeutics, Inc. | $1.5M | 0.18% | 2,759,344 | Common | SOLE |
| 84833T103 | SPRO | Spero Therapeutics, Inc. | $1.5M | 0.18% | 1,013,438 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.